SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-092738
Filing Date
2024-08-07
Accepted
2024-08-07 16:05:23
Documents
62
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q stok-20240630.htm   iXBRL 10-Q 1822765
2 EX-10.1 stok-ex10_1.htm EX-10.1 86752
3 EX-10.2 stok-ex10_2.htm EX-10.2 51173
4 EX-10.3 stok-ex10_3.htm EX-10.3 101994
5 EX-31.1 stok-ex31_1.htm EX-31.1 15790
6 EX-31.2 stok-ex31_2.htm EX-31.2 15600
7 EX-32.1 stok-ex32_1.htm EX-32.1 7867
8 EX-32.2 stok-ex32_2.htm EX-32.2 8649
  Complete submission text file 0000950170-24-092738.txt   6257948

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT stok-20240630.xsd EX-101.SCH 731914
64 EXTRACTED XBRL INSTANCE DOCUMENT stok-20240630_htm.xml XML 836071
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

IRS No.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38938 | Film No.: 241183564
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)